Arovella enhances solid tumour pipeline by licensing novel CAR-iNKT cell armouring technology
ArovellaTherapeutics Ltd is pleased to announce it has entered into a global, exclusive license with University of North Carolina Lineberger Comprehensive Cancer Center to incorporate a novel armouring cytokine technology (IL-12-TM) for its CAR-iNKT cell platform.
is the only company globally developing IL-12-TM armoured CAR-iNKT cells
This armouring cytokine technology:
results in a ten-fold increase in circulating CAR-iNKT cell numbers in animal models for solid tumours
significantly improved CAR-iNKT anti-tumour activity
significantly improved overall survival in animal models
enhances CAR-iNKT cells to potentially treat a range of solid tumour types
Patent applications filed to protect the technology until at least 2043
Arovella’s CEO and MD, Dr Michael Baker, commented: “We are incredibly excited to license the IL-12-TM technology from Professor Dotti’s laboratory for use with our CAR-iNKT cell platform. The data supporting solid tumours is compelling and will see Arovella enhance its solid tumour pipelines and effectiveness.”